2024-10-30 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report 

**1. Performance Comparison:**

Pfizer Inc. (PFE) has significantly underperformed the S&P 500 (VOO) over the provided period.  While the S&P 500 has generated a cumulative return of 136.74%, Pfizer has experienced a negative return of -13.18%, resulting in a total divergence of -149.92%. This puts Pfizer at the bottom of the historical performance range compared to the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** $28.46
* **5-Day Moving Average:** $28.65
* **20-Day Moving Average:** $29.02
* **60-Day Moving Average:** $29.01

The current price is below all three moving averages, indicating a possible downward trend.

**3. Technical Indicators:**

* **RSI:** 27.06 (Under 30, indicating oversold conditions)
* **PPO:** -0.27 (Negative, suggesting potential weakness)
* **Delta_Previous_Relative_Divergence:** -1.43 (-) (Short-term downward trend)

The technical indicators suggest a bearish outlook for Pfizer in the short-term. However, the oversold RSI could indicate a potential bounce back.

**4. Recent Earnings and Outlook:**

| Date | EPS | Estimated EPS |
|---|---|---|
| 2024-10-29 | 1.06 | 0.614 |
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |

Pfizer has consistently beaten earnings estimates for the past four quarters. The most recent earnings report (2024-10-29) showed an EPS of 1.06, exceeding the estimated EPS of 0.614. This suggests strong performance and potential for continued growth. 

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-06-30 | $13.28B | 75.16% |
| 2024-03-31 | $14.88B | 77.29% |
| 2023-12-31 | $14.25B | 46.92% |
| 2023-09-30 | $13.23B | 29.95% |
| 2023-06-30 | $13.01B | 75.11% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-06-30 | $87.70B | 0.05% |
| 2024-03-31 | $92.28B | 3.38% |
| 2023-12-31 | $89.01B | -3.78% |
| 2023-09-30 | $96.93B | -2.46% |
| 2023-06-30 | $99.02B | 2.35% |

Pfizer has shown strong revenue growth and profitability across recent quarters, with a notable decrease in Profit Margin in Q4 2023.  The ROE fluctuates, indicating potential variability in returns for investors.

**6. News and Recent Issues:**

**Recent Market Outlook for Pfizer:**

While Pfizer has faced challenges related to the slowdown in COVID-19 vaccine sales, the company has a strong pipeline of innovative drugs in various therapeutic areas like oncology, cardiovascular disease, and rare diseases. Investors are watching closely for the performance of these new products and their impact on revenue growth. 

**Analyst Opinions and Performance Highlights:**

According to FINBOLD, the average analyst rating for Pfizer is "Buy" with a consensus target price of $45.42.  Analysts highlight Pfizer's strong brand recognition, diversified product portfolio, and robust pipeline as key drivers for future growth. 

**7. Comprehensive Analysis:**

Pfizer's recent performance has been negatively impacted by the decline in COVID-19 vaccine sales.  However, the company remains a dominant player in the pharmaceutical industry with a strong pipeline of innovative drugs and a solid financial foundation.  While the stock has underperformed the S&P 500 in recent times, the strong earnings beat and favorable analyst sentiment suggest potential for future growth. The current oversold condition and technical indicators suggest a possible short-term bounce back. Investors seeking long-term exposure to the healthcare sector may consider adding Pfizer to their portfolio, but closely monitoring the company's progress in its key therapeutic areas is crucial.

**8. Expected Return:**

Based on current market conditions and long-term trends in the healthcare sector, Pfizer's expected return is estimated to be **0.0%** for the next 2 years. This indicates that, over the long term, the stock is expected to perform in line with the S&P 500. 
